# Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

> **NCT00759720** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 447 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** TAK-559 and glyburide
- **DRUG:** TAK-559 and glyburide
- **DRUG:** Glyburide

## Key facts

- **NCT ID:** NCT00759720
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-11
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 447 (ACTUAL)
- **Why stopped:** Potential hepatic safety signal
- **Last updated:** 2012-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759720, "Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00759720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*